214 related articles for article (PubMed ID: 21285153)
1. The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Calvert H; Azzariti A
Ann Oncol; 2011 Jan; 22 Suppl 1():i53-9. PubMed ID: 21285153
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
4. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors: its role in treatment of cancer.
Chen A
Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
[TBL] [Abstract][Full Text] [Related]
7. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
8. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Lord CJ; Tutt AN; Ashworth A
Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
[TBL] [Abstract][Full Text] [Related]
11. Inducing synthetic lethality using PARP inhibitors.
Boss DS; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
[TBL] [Abstract][Full Text] [Related]
12. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Frizzell KM; Kraus WL
Breast Cancer Res; 2009; 11(6):111. PubMed ID: 20017885
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Comen EA; Robson M
Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Plummer R
Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
[TBL] [Abstract][Full Text] [Related]
17. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
McCabe N; Lord CJ; Tutt AN; Martin NM; Smith GC; Ashworth A
Cancer Biol Ther; 2005 Sep; 4(9):934-6. PubMed ID: 16251802
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Banerjee S; Kaye S
Curr Oncol Rep; 2011 Dec; 13(6):442-9. PubMed ID: 21913063
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
